Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications
- 21 March 2011
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (1), 64-76
- https://doi.org/10.1111/j.1755-5949.2011.00245.x
Abstract
Clinical pharmaceutical trials aimed at modulating the immune system in Alzheimer's Disease have largely focused on either dampening down central proinflammatory innate immunity or have manipulated adaptive immunity to facilitate the removal of centrally deposited beta amyloid. To date, these trials have had mixed clinical therapeutic effects. However, a number of clinical studies have demonstrated disturbances of both systemic and central innate immunity in Alzheimer's Disease and attention has been drawn to the close communication pathways between central and systemic immunity. This paper highlights the need to take into account the potential systemic effects of drugs aimed at modulating central immunity and the possibility of developing novel therapeutic approaches based on the manipulation of systemic immunity and its communication with the central nervous system.Keywords
This publication has 101 references indexed in Scilit:
- TNF-α and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjectsJournal of Neuroimmunology, 2009
- Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little?Neuron, 2009
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Developing novel immunogens for a safe and effective Alzheimer's disease vaccineArts and The Brain: Psychology and Physiology Beyond Pleasure, 2009
- Amyloid-β immunisation for Alzheimer's diseaseThe Lancet Neurology, 2008
- Systemic Inflammation Induces Acute Behavioral and Cognitive Changes and Accelerates Neurodegenerative DiseaseBiological Psychiatry, 2008
- Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's diseaseBrain Research, 2008
- PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's DiseaseNeurotherapeutics, 2008
- Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging studyAnnals of Neurology, 2002
- Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid βBiochemical and Biophysical Research Communications, 1994